Team

Steve Gourlay

Partner

Dr Steve Gourlay joined GBS in 2005 with more than 15 years experience in drug development. Most recently he was Senior Director of Clinical & Experimental Pharmacology and (Preclinical) Safety at Genentech Inc. in California. Over the same period Steve taught epidemiology, clinical research methods and clinical pharmacology at Monash University and the University of California, San Francisco. At Genentech he contributed to the preclinical and clinical sections of successful new drug applications for Xolair™, Avastin™, and Raptiva™ and supervised six IND applications. Steve is on the board of directors of GBS portfolio companies AiMedics Pty Ltd, Applied Physiology Ptd Ltd, Endoluminal Science Pty Ltd and Elastagen Ptd Ltd.

Steve is a licensed consultant physician in Internal Medicine. He received his PhD from Monash University after completing a series of observational and interventional studies of novel smoking cessation medications. Subsequently he undertook a postdoc in clinical pharmacology at UCSF and a MBA at Macquarie University. He has published more than 30 peer-reviewed reports of clinical research.